Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Agrees to use an acceptable method of contraception for the duration of the study~* Subject has completed the 24-week treatment period in the antecedent study, ALK3831-A303, within 7 days~* Additional criteria may apply~Exclusion Criteria:~* Subject is currently taking medications that are contraindicated with olanzapine use or exhibit drug-interaction potential with olanzapine~* Subject has a positive test for drugs of abuse at study entry~* Subject is pregnant, planning to become pregnant, or breastfeeding during the study~* Additional criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- ALKS 3831 (Type: EXPERIMENTAL): Oral tablet, daily dosing

Based on this trial design, predict the completion outcome and termination type (if applicable).